Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

723
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
723
T Cell Types and Functions01:24

T Cell Types and Functions

1.5K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.5K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

8.1K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
8.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

4.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal dynamics of immune effector cell-associated haematotoxicity: Linking early and late cytopenias after chimeric antigen receptor T cells.

British journal of haematology·2026
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

[Attractiveness of the clinical hematology specialty in France: A cross-sectional perspective from medical students, residents, and practicing hematologists].

Bulletin du cancer·2026
Same author

Clonal expansion of CAR-T cells harboring lentivector integration in the PLAAT4 gene following anti-CD19 CAR T-cell therapy in a context of cutaneous T-cell lymphoma.

Haematologica·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026

Related Experiment Video

Updated: Oct 9, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.0K

[CAR-T cells in lymphomas: Current and evolving role].

Ondine Messéant1, Roch Houot1

  • 1CHU de Rennes, University of Rennes, Department of Hematology, 2, rue Henri-le-Guilloux, 35000 Rennes, France.

Bulletin Du Cancer
|December 18, 2021
PubMed
Summary

Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized treatment for diffuse large B cell lymphomas (DLBCL). This review covers the latest efficacy, toxicity, and resistance data for CAR-T cells in various lymphomas.

Keywords:
CAR-T cellImmunotherapyImmunothérapieLymphomaLymphome

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

861

Related Experiment Videos

Last Updated: Oct 9, 2025

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

861

Area of Science:

  • Oncology
  • Immunotherapy
  • Hematology

Background:

  • Chimeric antigen receptor T-cell (CAR-T) therapies, including Yescarta®, Kymriah®, and Breyanzi®, are approved for relapsed or refractory diffuse large B cell lymphomas (DLBCL) after failure of prior treatments.
  • These immunotherapies offer a transformative approach for lymphomas resistant to conventional therapies.

Purpose of the Study:

  • To review the latest clinical data on CAR-T cell therapy in various B-cell lymphomas.
  • To discuss the efficacy, toxicity, resistance mechanisms, and evolving therapeutic strategies involving CAR-T cells.

Main Methods:

  • Review of long-term follow-up data from registration studies of approved CD19 CAR-T cells.
  • Analysis of real-world evidence on CAR-T cell therapy outcomes.
  • Examination of ongoing research into CAR-T cell applications for other lymphoma subtypes.

Main Results:

  • CAR-T cell therapies have significantly improved outcomes in DLBCL.
  • Real-world data corroborate the efficacy and provide insights into toxicity and resistance.
  • Expanding indications include mantle cell and indolent lymphomas with recent approvals (Yescarta®, Tecartus®).

Conclusions:

  • CAR-T cell therapy is a cornerstone in treating relapsed/refractory DLBCL and is expanding to other B-cell malignancies.
  • Ongoing research aims to develop CAR-T cells for Hodgkin's and T-cell lymphomas.
  • Further data are needed to fully establish the role of CAR-T cells in these settings.